Histone Deacetylase (HDAC) Inhibitors Market Anticipated To Witness Robust Growth, Surpassing $1.77 Billion By 2029

The Histone Deacetylase (HDAC) Inhibitors Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Current Histone Deacetylase (HDAC) Inhibitors Market Size and Its Estimated Growth Rate?
The histone deacetylase (HDAC) inhibitors market has experienced strong growth in recent years. It will grow from $1.23 billion in 2024 to $1.33 billion in 2025 at a CAGR of 7.9%. The growth in the historic period can be attributed to increased funding for epigenetic research, the rising prevalence of drug-resistant cancers, higher healTH*Care expenditure, increasing use of HDAC inhibitors in veterinary medicine, and greater investment in bioinformatics.

The histone deacetylase (HDAC) inhibitors market is expected to experience significant growth in the coming years, reaching $1.77 billion by 2029 with a CAGR of 7.5%. The growth can be attributed to the rising incidence of neurodegenerative disorders, growing awareness about cancer, increasing investment in drug development, a growing number of clinical trials, and the adoption of personalized medicine. Major trends include technological advancements, the integration of personalized medicine, synergies with cancer immunotherapy, the incorporation of digital health solutions, and advancements in bioinformatics.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18386

How Are Emerging Segments Shaping the Histone Deacetylase (HDAC) Inhibitors Market Landscape?
The histone deacetylase (HDAC) inhibitors market covered in this report is segmented -

1) By Class: Class I HDACs, Class II HDACs, Class III HDACs, Class IV HDACs
2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors
3) By Application: Oncology, Neurology, Other Applications
4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users

Subsegments
1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8
2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10
3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7
4) By Class IV HDACs: HDAC11

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp

Which Growth Factors Are Influencing Histone Deacetylase (HDAC) Inhibitors Market Expansion?
The rising incidence of neurodegenerative disorders is also expected to drive the histone deacetylase (HDAC) inhibitors market. Neurodegenerative diseases like Alzheimer's are becoming more prevalent due to factors such as aging, genetics, and environmental influences. HDAC inhibitors, which help modulate gene expression, are being explored for their neuroprotective effects in treating conditions like Alzheimer's. The CDC reports that 6.7 million older adults in the U.S. live with Alzheimer's, a number expected to rise to nearly 14 million by 2060, further boosting the need for HDAC inhibitors in treatment.

Who Are the Dominant Players Across Different Histone Deacetylase (HDAC) Inhibitors Market Segments?
Major companies operating in the histone deacetylase (HDAC) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.

What Are the Latest Developing Trends in the Histone Deacetylase (HDAC) Inhibitors Market?
Major firms in the histone deacetylase (HDAC) inhibitors market are concentrating on the development of innovative therapies, including HDAC inhibitors for cancer, to boost effectiveness and lessen adverse effects. HDAC inhibitors, a category of medical compounds utilized in cancer therapy, operate by constraining the function of HDAC enzymes, generally responsible for removing acetyl groups from histone proteins. This restriction results in the heightened acetylation of histones, reshaping chromatin form and impacting gene expression. For example, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based organization that pioneers first-in-class cancer treatments, received New HDAC Inhibitor Patents for Cancer Treatment from the U.S. Patent and Trademark Office. These pioneering inhibitors are engineered to aim at particular HDAC enzymes implicated in cancer evolution, intending to interrupt abnormal gene expression sequences that further tumor growth and spread. The patented compounds showcase heightened strength and discernment, reducing off-target impacts and enhancing patient safety profiles during therapy.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/histone-deacetylase-hdac-inhibitors-global-market-report

Which Geographic Regions Are Expected to Dominate the Histone Deacetylase (HDAC) Inhibitors Market in the Coming Years?
North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Histone Deacetylase (HDAC) Inhibitors Market?
2. What is the CAGR expected in the Histone Deacetylase (HDAC) Inhibitors Market?
3. What Are the Key Innovations Transforming the Histone Deacetylase (HDAC) Inhibitors Industry?
4. Which Region Is Leading the Histone Deacetylase (HDAC) Inhibitors Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.